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8 The Journal of Thoracic and Cardiovbjectives: The objectives of this study were to measure circulating N-terminal
-type natriuretic peptide levels in pediatric patients undergoing surgical repair of
ongenital heart lesions with left ventricular volume overload and to determine
hether presurgical and immediate postoperative N-terminal B-type natriuretic
eptide levels could predict patient outcomes after surgical intervention.
ethods: Thirty-eight children aged 1 to 36 months undergoing surgical repair of
ardiac lesions with left ventricular volume overload were studied. Plasma N-
erminal B-type natriuretic peptide levels were measured preoperatively and at 2, 12,
4, 48, and 72 hours after surgical intervention and were assessed for their predic-
ive value of postoperative outcomes. Plasma N-terminal B-type natriuretic peptide
evels were also measured in 34 similarly aged healthy children.
esults: Patient preoperative N-terminal B-type natriuretic peptide levels were
ignificantly higher than those of healthy control subjects (3085  4046 vs 105 
8 pg/mL). Preoperative N-terminal B-type natriuretic peptide levels correlated with
he complexity of surgical repair, as measured by cardiopulmonary bypass time (r
.529, P  .001), and with postoperative measures, including fractional inhaled
xygen requirements registered at 12 hours (r  0.443, P  .005) and duration of
echanical ventilation (r  0.445, P  .005). Plasma N-terminal B-type natriuretic
eptide levels increased 5-fold within 12 hours after cardiopulmonary bypass
14,685  14,317 pg/mL). Multivariable regression analysis showed that the pre-
perative N-terminal B-type natriuretic peptide level was a significant predictor of
uration of intensive care unit stay (P  .02) and that the peak postoperative
-terminal B-type natriuretic peptide level was a significant predictor of the inten-
ity of overall medical management, as assessed by using the therapeutic interven-
ion scoring system (P  .01).
onclusion: Plasma N-terminal B-type natriuretic peptide levels measured preop-
ratively and postoperatively can be a prognostic indicator in the management of the
ediatric patient after surgical intervention for congenital heart repair.
 
he natriuretic peptides, of which atrial natriuretic peptides and bra
B-type natriuretic peptide (BNP) are of myocardial cell origin, play a
significant role in the control of volume homeostasis and regulation of blood
ressure.1-3 Plasma levels of the cardiac natriuretic peptides have been show
ncrease with congestive heart failure in adults and to correlate with the severity of
isease, thus providing an indirect measure of left ventricular (LV) function.4-6 The
iologically inactive prohormone of BNP (proBNP), is secreted by cardiac ventric-
lar myocytes in response to volume and pressure overload7 an  is enzymatically
leaved to the physiologically active form, BNP, and the inactive N-terminal
ragment, NT-pro-BNP or N-BNP, in a one-to-one ratio.8-10 Circulating levels of
ascular Surgery ● January 2008
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Doth BNP and N-BNP have been shown to be increased in
arly cardiac dysfunction in adults, making it a useful pre-
ictor of congestive heart failure in hypertrophic or dilated
ardiomyopathy4,5,11-14 and a prognostic indicator of o-
ome in congestive heart failure.15-18 The recent commer-
ial development of a diagnostic N-BNP assay was based on
he greater in vitro stability of this moiety compared with
hat of BNP and with the longer half-life of circulating
-BNP, making it a reliable marker of cardiac function19,20
Recently, measurements of either BNP or N-BNP as
erioperative markers of ventricular function or as prognos-
ic indicators of postoperative outcomes in pediatric patients
ith congenital heart disease have been explored.21-24 How-
ver, only limited data exist regarding the effects of LV
olume overload on the circulating levels of N-BNP in
ediatric patients with congenital heart disease. Therefore,
he primary goal of this study was to measure circulating
evels of N-BNP in pediatric patients with LV volume
verload who were undergoing cardiac surgery with cardio-
ulmonary bypass (CBP) and to correlate preoperative and
ostoperative N-BNP levels with outcome measures to as-
ess the utility of N-BNP as a reliable marker of postoper-
tive clinical status of the pediatric cardiac patient.
aterials and Methods
tudy Inclusion Criteria and Diagnostic Classifications
his prospective study was conducted at Schneider Children’s
ospital and was approved by the institutional review board of the
orth Shore Long Island Jewish Health System. Written informed
onsent was obtained from parents or guardians before recruitment
nto the study. Sixty-seven pediatric patients with congenital heart
efects known to cause LV volume overload scheduled for com-
lete surgical repair were identified between September 2004 and
ovember 2005 as eligible for enrollment into this study. Thirty-
ight of these patients who are included in the present analysis
ere 3 years of age and younger and had lesions including ven-
ricular septal defect (VSD) and complete common atrioventricular
anal (CCAVC). Patients with single-ventricle physiology and
bstructive lesions, such as aortic stenosis or coarctation of the
orta, were excluded from the study. Evidence of preoperative
enal insufficiency, as indicated by measures of blood urea nitro-
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
CCAVC complete common atrioventricular canal
CPB  cardiopulmonary bypass
LV  left ventricle
N-BNP  N-terminal B-type natriuretic peptide
PICU  pediatric intensive care unit
TISS  Therapeutic Intervention Scoring System
VSD  ventricular septal defecten and creatinine, precluded participation. t
The Journal of ThoracControl subjects were recruited from healthy patients evaluated
uring well-care visits to the pediatric clinic at Schneider Chil-
ren’s Hospital. Written informed consent was obtained before
nrollment in this study. A history of acute or chronic illness, any
rior cardiac disease, or both precluded participation. All subjects
ad normal physical evaluations and no clinical evidence of con-
enital heart disease. Blood samples were drawn after the clinical
valuation for subsequent analysis of N-BNP levels.
ata Collection
linical data were prospectively collected on intraoperative pa-
ameters and postoperative outcomes. Surgical procedures, includ-
ng CPB and anesthesia, followed standard practices, and postop-
rative patient management in the pediatric intensive care unit
PICU) were based on standard institutional protocol without
nowledge of patient N-BNP test values. Presurgical blood sam-
les were obtained from enrolled patients during outpatient pre-
urgical routine blood analysis. After surgical intervention, pa-
ients were admitted to the PICU, with the majority of patients
eceiving mechanical ventilator support. Blood samples were
rawn from central intravenous catheters at 2, 12, 24, 48, and 72
ours after termination of CPB or until the catheters were re-
oved. Therefore, N-BNP analysis at later time points was not
btained on all patients because of the removal of central intrave-
ous lines. Blood samples were processed immediately, and the
lasma was stored at 20°C until all samples could be ana-
yzed. Plasma N-BNP levels were measured with a commer-
ially available electrochemiluminescence immunoassay kit
Elecsys proBNP, Roche Diagnostics, NJ).
Patients were continuously monitored in the PICU, and clinical
ata, including quantities of vasodilator and inotropic drugs, blood
as and lactate analyses, oxygen requirement, urine output, blood
ressures, cardiac rhythm, and heart rate, were recorded daily.
hese values were among 76 different therapeutic and monitoring
rocedures used to assess the overall degree of postoperative care,
s calculated by using the Therapeutic Intervention Scoring
ystem (TISS).25 TISS scores were derived over a 24-hour pe
nd reflected the invasiveness, intensity, and complexity of care
endered to the patient in the PICU. Inotropic scores were obtained
t 24, 48, and 72 hours after CPB by using a modification of the
alculation described by Wernovsky and colleagues26: Dopamine 
obutamine  ([Epinephrine  Norepinephrine])  100. The
aily inotropic score was calculated by obtaining the total amount
f inotropic drug administered in a 24-hour period and expressed
s micrograms per kilogram per minute.
tatistical Analysis
lasma N-BNP values were compared between the healthy control
roup and the presurgical values of the study patients by using t
ests. A repeated-measures analysis of variance was carried out to
ompare N-BNP values collected over time (preoperatively and
ostoperatively at 2, 12, 24, 48, and 72 hours) for the surgical
atients. Tukey-adjusted pairwise comparisons were carried out to
etermine which time points significantly differed from one an-
ther. Because age was considered as a potential confounder, all
nalyses made an adjustment for age by using age as a covariate.
t was determined that a log transformation of the data conformed
o the standard ANOVA assumptions. Accordingly, all analyses
ic and Cardiovascular Surgery ● Volume 135, Number 1 99
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Dere conducted with the log-transformed data, but summaries and
raphs are presented in the original untransformed units of mea-
urement to facilitate interpretation. Correlation coefficients be-
ween the highest or peak N-BNP plasma level and each of the
ostoperative clinical measures were calculated by using Spear-
an correlation.
A multivariate regression analysis with a backward elimination
lgorithm was used to determine the best predictor or predictors
eparately for days in the PICU, ventilation time, and cumulative
ISS score. Two sets of candidate variables were used: the first set
ncluded only variables known before surgical intervention, in-
luding age, lesion type, and preoperative N-BNP value, and the
econd set included variables known before surgical intervention
nd variables known by the second postoperative day, including
ge, lesion type, preoperative N-BNP value, CPB time, and peak
ostoperative N-BNP value.
esults
tudy Group Characteristics and Study Outcomes
able 1 shows the types of congenital heart lesions of 
atients enrolled in the study, with the majority (79%)
aving VSD and 21% having CCAVC. There was no dif-
ABLE 1. Study subject demographics and characteristics
Healthy subjects (n) 34
Age (mo) 19.6  9.1 (24; 2.4–36)*
Sex Female, 44%; male, 56%
Surgical patients (n) 38
Age (mo) 7.1  8.3 (4.0; 1–36)*
Sex Female, 47%; male, 53%
Weight (kg) 6.3  4.9 (4.4; 2.5–26.5)*
Anatomic defects (n)
VSD 30
CCAVC 8
SD, Ventricular septal defect; CCAVC, complete common atrioventricular
anal. *Mean  SD (median; minimum-maximum).
ABLE 2. Intraoperative and postoperative parameters
VSD (n 
Intraoperative data*
CPB time (min) 84 2
Crossclamp time (min) 48 1
Postoperative outcomes*
Intensive care unit stay (d) 4.0 2
Mechanical ventilation (h) 14.3 1
Hospital stay (d) 5.6 3
TISS (cumulative POD 1-3) 66.3 1
IS (cumulative POD 1-3) 2.9 3
FIO2 at 2 h 58  2
Preoperative N-BNP (pg/mL) 2739 4
Peak N-BNP (pg/mL) 14,845 1
Mean  standard deviation. ns  not significant. VSD, Ventricular septal
ypass; TISS, Therapeutic Intervention Scoring System; POD 1-3, postoperative
00 The Journal of Thoracic and Cardiovascular Surgery ● Janu8
erence in the mean age of the patient groups between the 2
ypes of lesions, but the mean body weight of the CCAVC
roup was lower than that of the VSD group (4.2  2.0 vs
.9 5.3 kg, P .05). The weight-for-age percentiles of 29
76%) of the 38 patients were less than the 10th percentile,
ith none greater than the 50th percentile, a criterion indicative
f significant heart failure. The healthy control subjects were
imilarly 3 years of age and younger; however, the healthy
roup was significantly older than the surgical patient group
19.6 9.1 vs 7.1 8.3 months, respectively; P .001). Sex
istribution was not different between the groups.
Table 2 lists intraoperative and postoperative outcom
ata grouped by the type of cardiac lesion. Significant
ifferences were found between the 2 lesion types, with
onger CPB and crossclamp times recorded for the CCAVC
roup. Although both preoperative and peak postoperative
lasma N-BNP levels were not significantly different be-
ween groups, both values tended to be higher in the patients
ith CCAVC. Significantly longer mechanical ventilation
ime, hospital stays, inotropic scores, and TISS scores were
ecorded for patients with CCAVC lesions.
reoperative Plasma N-BNP Levels and Response to
urgical Intervention
ealthy subjects had a mean plasma N-BNP value of 105
8 pg/mL, whereas the 38 patients with LV volume over-
oad had a significantly higher mean presurgical N-BNP
alue of 3085  4046 pg/mL (P  .001) (Figure 1; Tabl
). The presurgical N-BNP values did not differ sig
antly with lesion type (Table 2) and were inversely c
ated with patient age (r  0.672, P  .0001), indicating
hat younger patients with heart failure had higher circulat-
ng levels of N-BNP before corrective operations.
In response to surgical intervention, circulating N-BNP
evels did not increase immediately after discontinuation of
CCAVC (n  8) P value
134  29 .01
97 28 .01
6.3 5.0 NS
50.3 35 .01
18.8  29.1 .01
90.5 14.7 .01
13.2  9.3 .01
70 26 NS
4382 3873 NS
20,482 12,879 NS
t; CCAVC, complete common atrioventricular canal; CPB, cardiopulmonary30)
9
9
.0
1.7
.5
9.1
.5
3
084
4,800
defec
days 1 to 3; IS, inotropic score; FIO2, fraction of inhaled oxygen.
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DPB (2 hours; 3178  4366 pg/mL) but did increase sig-
ificantly when measured at 12 hours after CPB (14,685 
4,317 vs preoperative value of 3085  4046 pg/mL, P 
0001) and remained significantly higher at 24 and 48 hours
P  .0001) and at 72 hours (P  .005, Figure 1; Table 3
he plasma N-BNP levels in each patient reached a maxi-
um value at either 12 or 24 hours after surgical interven-
ion, and these peak N-BNP values correlated significantly
ith CPB time (r  0.400, P  .01), suggesting that the
omplexity and duration of the surgical repair procedure, as
eflected by CPB time, might have been determining factors
n the magnitude of the induction of N-BNP synthesis and
elease.
reoperative N-BNP and Peak N-BNP Values as
redictors of Clinical Outcomes
orrelation analysis between clinical outcomes and preop-
TABLE 3. Plasma N-terminal B-typ
Time point n
CTL 34
Patients
Pre 38
2 h 34
12 h 33
24 h 29
48 h 16
72 h 4
*p  0.001 vs CTL. †p  0.0001 vs Pre andrative or peak N-BNP values showed that results using all a
The Journal of Thoracic8 patients were similar to results from the 30 patients with
SDs; therefore we present only the data from the com-
ined patient groups.
The preoperative N-BNP values correlated significantly
ith CPB time (r  0.529, P  .0006), suggesting that the
everity of the lesion or volume overload, as measured on
he basis of increased circulating preoperative N-BNP lev-
ls, reflected the complexity of the surgical repair proce-
ure. Preoperative N-BNP levels correlated with several
utcome measures, including length of time supported by
echanical ventilation (r  0.445, P  .005), fraction of
nspired oxygen registered at 12 hours (r  0.445, P 
005), length of hospital stay (r  0.487, P  .002), and
ays in the PICU (r  0.435, P  .006; Figure 2, A). The
umulative TISS score, reported as the sum of 24-hour
cores recorded during the first 72 hours after surgical
ntervention, correlated positively with circulating preoper-
triuretic peptide levels
Mean  SD (pg/ml)
105 78
3085 4046*
3178 4366
14685 14317†
11891 8582†
12331 10960†
10645 6296‡
p  0.005 vs Pre and 2 h.
Figure 1. Circulating N-terminal B-type natri-
uretic peptide (N-BNP ; in picograms per millili-
ter) in control (CTL) healthy children and in pe-
diatric patients before and after cardiopulmonary
bypass (CPB) surgery. The box plot encompasses
the 25th to 75th percentiles, the horizontal line is
the median value, and the caps represent the
10th and 90th percentiles.e native N-BNP levels (r  0.412, P  .01).
and Cardiovascular Surgery ● Volume 135, Number 1 101
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DMultivariable regression analysis with variables known
nly before surgical intervention, including preoperative
-BNP values, age in months, and lesion type, showed that
he preoperative N-BNP value was a moderate predictor of
he number of days spent in the PICU (P  .02), regardless
f lesion type. Type of lesion (VSD or CCAVC), however,
as a highly significant predictor of cumulative TISS score
P  .002) and days of mechanical ventilation (P  .0008).
In support of the hypothesis that the N-BNP response to
urgical intervention can predict clinical outcomes, signifi-
ant positive correlations were observed between peak N-
NP values and the total time required for mechanical
entilator support (r  0.454, P  .004), length of hospital
tay (r  0.571, P  .0002), and days in the PICU (r 
.492, P  .002; Figure 2, B). Furthermore, the peak N
NP value correlated with the intensity of overall medical
anagement in the postoperative period, as assessed by
sing the cumulative TISS score (r  0.460, P  .004;
igure 2, C). Multivariable regression analysis with va
bles known before surgical intervention, as described
bove, and variables known within 24 hours after surgical
ntervention, including peak N-BNP value and CPB time,
howed that peak N-BNP value was a significant predictor
f days in the PICU (P  .01) and the cumulative TISS
core (P  .01).
iscussion
n this study we used a commercially available N-BNP
ssay to assess outcomes of pediatric patients undergoing
urgical repair of cardiac lesions involving LV volume
verload. The salient observations of the present study are
s follows: (1) preoperative circulating levels of N-BNP
ere significantly increased in pediatric patients with le-
ions producing LV volume overload compared with those
een in healthy children; (2) preoperative N-BNP levels
orrelated with the complexity of surgical repair, as as-
essed by using intraoperative variables, including CPB
ime; (3) multivariable regression analysis with variables
nown before surgical intervention showed that the preop-
rative N-BNP level was a significant predictor of length of
tay in the PICU; and (4) multivariable regression analysis
ith variables known preoperatively and within 24 hours
ostoperatively showed that the postoperative peak N-BNP
evel was predictive of TISS scores. This study also estab-
ished a range of normal values for N-BNP in a cohort of
ealthy children of similar age, with a mean value of 105 
8 pg/mL, which is similar to that previously publishe27
Kunii and associates28 investigated the relationship be-
ween circulating BNP levels and LV volume overload
esions. They reported a significant correlation between
NP levels and the severity of disease and addressed the
tility of BNP measurements in evaluating surgical indica-igure 2. Preoperative and postoperative plasma N-terminal B-
ype natriuretic peptide (N-BNP) levels predict postoperative
utcomes. Preoperative N-terminal B-type natriuretic peptide lev-
ls showed significant positive correlation with days spent in the
ediatric intensive care unit (PICU; A). Peak postoperative N-
erminal B-type natriuretic peptide levels showed significant
orrelation with PICU days (B) and with the TISS score summed
rom postoperative days 1 to 3 (cumulative POD1-3; C). The lineions. In the present study we focused our study on lesions
ary 2008
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Dausing LV volume overload, specifically VSD and
CAVC. All of these patients were well below the normal
eight-for-age percentile, with the patients with CCAVC
elow the fifth percentile, indicating significant heart fail-
re. Even within this homogeneous group of lesion types,
he patients with CCAVC exhibited higher preoperative
-BNP levels and higher postoperative peak N-BNP that
orrelated with longer CPB times, perhaps reflecting more
omplicated surgical repairs. These patients required signif-
cantly greater postoperative medical care, as reflected in
igher TISS scores, increased inotropic requirements, and
onger duration of mechanical ventilation.
To determine which variables were the best predictors of
utcomes, we tested 2 types of multivariable regression
odels: (1) a model using only variables known before
urgical intervention (lesion type, age, and preoperative
-BNP level) and (2) a model using variables known before
urgical intervention and at 24 hours after surgical interven-
ion, including CPB time and peak postoperative N-BNP
evel. By using multivariable regression analysis with days
n the PICU, cumulative TISS score, and duration of me-
hanical ventilation as the dependent variables, only the
esion type was a significant predictor of duration of me-
hanical ventilation (P  .001) and cumulative TISS score
P  .002) in both models. The preoperative N-BNP level
as a significant predictor of length of stay in the PICU,
hereas the postoperative peak N-BNP level was a signif-
cant predictor of days in the PICU and cumulative TISS
core. When lesion type was eliminated from the equation
y examining only the VSD group, the results were similar,
ith the peak N-BNP level remaining a significant predictor
f TISS score and PICU days, whereas the preoperative
-BNP level remained in the model for predicting length of
tay in the PICU. Absolute values of presurgical and post-
perative peak N-BNP that could potentially be used to
dentify those patients at risk will require analysis of a much
arger data set. However, data from this study and several
ther recently published reports support the potential pre-
ictive value of perioperative BNP and N-BNP measure-
ents in determining the intensity of postoperative medical
anagement, including inotrope requirements,24 vasodila-
or support,22 and duration of mechanical ventilation time21
Increases in circulating N-BNP levels after CPB were
nticipated, with peak postoperative N-BNP levels correlat-
ng with CPB duration (r  0.400, P  .01). Cardiac
urgery involving CPB triggers a systemic inflammatory
esponse that involves the activation of lymphocytes, mono-
ytes, endothelial cells, and cardiac myocytes that can pro-
uce many proinflammatory cytokines.29,30 Whether myo-
ardial secretion of BNP is also a response to inflammation
s not known; however, inflammation-mediated changes in
ulmonary and systemic vascular pressures that occur after
PB26,31 can result in increased myocardial BNP produc- d
The Journal of Thoracicion and secretion. Proinflammatory cytokines have been
hown to upregulate cardiac-derived BNP,32,33 and as w
ave previously published, pediatric cardiac surgery with
PB activates numerous proinflammatory cytokines.34 Fur-
hermore, CPB in infants with congestive heart failure has
een reported to alter the biologic activity of the natriuretic
ormones, but the underlying mechanism for this phenom-
non remains unknown.35
Although the duration of CPB is a risk factor for mor-
idity after pediatric cardiac surgery, understanding of the
omplex pathophysiology of pulmonary dysfunction after
PB continues to be incomplete. Large intracardiac shunts
ith increased pulmonary blood flow will produce larger
V volume overload. In a previous report BNP levels were
ositively correlated with high Qp/Qs ratios in patients with
SD combined with patent ductus arteriosus.28 Thus in th
resent study patients with high preoperative N-BNP levels
nd subsequent high postoperative N-BNP levels, poten-
ially because of complicated surgical repairs and long CPB
imes, had ensuing pulmonary dysfunction with longer ven-
ilator requirements.
Circulating N-BNP levels increase on the first day of life
n neonates, potentially related to increased systemic vas-
ular resistance and pulmonary blood flow after birth36 and
ncreased pulmonary artery pressures among premature in-
ants.37 Higher levels of BNP and N-BNP have been-
orted in the neonatal population when compared with older
hildren.22,28,36 The median age of patients in the pre
tudy was 4 months, with a range of 1 to 36 months.
ecause age was considered a potential confounder, all
nalyses made an adjustment for age by using age as a
ovariate. Patient age was not significantly different be-
ween the VSD and CCAVC groups; however, many post-
perative outcome variables were significantly different,
ndicating that age per se was not predictive of surgical
utcomes but that the pathophysiology of the cardiac lesion
as a confounding factor.
There are several limitations in the present study, includ-
ng the use of therapeutic indexes and clinical scoring
ystems to assess cardiovascular and pulmonary functions
mmediately after surgical intervention because access for
irect measurement of cardiac output is limited in very
oung patients. Furthermore, studies involving larger num-
ers of patients will likely be necessary to generate absolute
alues of circulating N-BNP to identify at-risk patients and
o determine timing for surgical intervention. Our analyses
ave led to the overall conclusion that high circulating
-BNP levels before surgical intervention reflect the extent
f volume overload, ventricular distention, and cardiac
tress and that the postoperative N-BNP levels are in re-
ponse to CPB times and the complexity of surgical proce-
ures necessitated by the nature of the congenital heart
efect. Because plasma BNP levels have been correlated to
and Cardiovascular Surgery ● Volume 135, Number 1 103
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Dhunt volume in children with congenital septal defec38
e anticipate that BNP levels would return to normal values
fter remodeling of the myocardium after surgical repair
hat would occur after several weeks or months.
In conclusion, the present study confirms the findings of
ecent investigations21-24 supporting the potential prognos-
ic utility of preoperative and postoperative BNP or N-BNP
easurements in determining surgical risk and postopera-
ive outcomes in pediatric patients.
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